Saxenda

Saxenda is liraglutide 3 mg, a once-daily subcutaneous injection from Novo Nordisk. It was FDA-approved for chronic weight management in December 2014, making it the first GLP-1 specifically indicated for obesity in the modern era (preceded only by sibutramine and orlistat, which operated on entirely different pathways).

Liraglutide is a shorter-acting GLP-1 receptor agonist than semaglutide — about a 13-hour half-life, versus a week for semaglutide. That's why it's daily, not weekly.

In 2014, Saxenda was revolutionary. Today it's a third-tier drug by efficacy but still fills specific niches: pediatric treatment, cost-constrained patients, and the rare patient who responds better to liraglutide than semaglutide (uncommon but real). The liraglutide patent expired in 2024, and generic daily liraglutide is now available under several labels, cutting cost roughly in half.

The SCALE (Satiety and Clinical Adiposity — Liraglutide Evidence) trial program underpinned Saxenda's approval. SCALE Obesity and Prediabetes (N=3,731, 56 weeks) showed mean weight reduction of 8.0% on liraglutide 3 mg versus 2.6% on placebo. Real-world studies have generally found 5–8% over a year.

That is meaningfully worse than semaglutide (~15%) and tirzepatide (~22%). For most patients, Saxenda is no longer the obvious first-line choice in 2026.

The pediatric SCALE Teens trial (N=251, ages 12–17) showed about 5% weight reduction on drug vs placebo — modest but sufficient for the FDA pediatric approval. No other GLP-1 is currently FDA-approved for adolescents.

Saxenda titrates weekly: 0.6 mg → 1.2 mg → 1.8 mg → 2.4 mg → 3.0 mg (maintenance), one step per week. Full escalation takes 5 weeks — faster than weekly GLP-1s because the daily pharmacokinetics reach steady state sooner.

Daily injection means more needle events per year than weekly drugs but smaller peak-to-trough variability, which some patients find produces less pronounced nausea.

Side effect profile is class-typical: nausea (39% in SCALE), diarrhea, vomiting, constipation, injection-site reactions. Boxed warning for thyroid C-cell tumors applies. Class safety considerations mirror Wegovy/Ozempic.

This is where Saxenda earns its remaining market share.

Brand Saxenda list price: about $1,349/month — high.

Generic liraglutide 3 mg (available from multiple manufacturers post-2024): $299–$499/month cash-pay, frequently lower with discount cards (GoodRx, SingleCare) and telehealth programs.

Insurance: most commercial plans that cover Wegovy will also cover Saxenda, often preferring generic liraglutide on formulary. Copays of $25–$60/month are common with brand savings cards or generic copay tiers.

Medicare/Medicaid: same obesity-drug carve-out as Wegovy applies to brand Saxenda. Generic liraglutide sometimes slips through on Medicaid formularies at lower tiers; check your state.

For a cash-constrained patient who wants a brand-name, FDA-approved, clinic-administered obesity drug and can tolerate daily injections, generic liraglutide is the cheapest legitimate option on the U.S. market.

Saxenda is a reasonable first-line choice when:

• Cost is the deciding factor and compounded alternatives aren't acceptable.
• The patient is 12–17 years old — Saxenda is the only FDA-approved GLP-1 in this age group.
• The patient has failed or not tolerated semaglutide but wants to stay in the GLP-1 class.
• Prior liraglutide exposure was successful and the patient prefers to stick with it.

It's the wrong drug for most other situations. A patient paying cash and wanting best weight loss should usually go with compounded tirzepatide via a lower-cost program, or Zepbound via LillyDirect Self Pay. Daily injection fatigue is real and shows up around month 6.

All standard channels: PCP or obesity medicine clinic + retail pharmacy; telehealth programs including Mochi, Ro, and Form Health; or direct from NovoCare. Generic liraglutide is available at most major pharmacy chains and mail-order; cash discount cards typically beat insurance copays for the generic.